Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan

Lin, Po-Lin; Wu, Yen‐Wen; Lin, Chao‐Feng; Yeh, Hung‐I; Chang, Wei‐Ting; Charng, Min‐Ji; Huang, Po‐Hsun; Lin, Chih‐Chan; Lin, Tsung‐Hsien; Lin, Wei-Wen; Hsieh, I‐Chang; Kuo, Feng-Yu; Chen, Ching-Pei; Li, Yi‐Heng

doi:10.5551/jat.63789

Cited by 4 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using real-world data, Lin et al showed a slightly lower LDL-C reduction effect from PCSK9 inhibitors compared with the clinical trial data 5) . One potential reason for the reduced LDL-C lowering effects, the authors highlight, is a pattern of spacing out injection times for each PCSK9 inhibitor due to its high cost.…”

Section: See Article Vol 30: 000-000mentioning

confidence: 99%

“…Given the current state, driven to some degree by "ability and willingness to pay" for PCSK9 inhibitors, what can we do to more effectively deliver this useful but relatively expensive drug to the right patients? Lin et al concluded in their paper that we need to find ways to tackle the reimbursement restriction together with physicians, governments, insurance systems, and pharmaceutical companies 5) .…”

Section: See Article Vol 30: 000-000mentioning

confidence: 99%

See 1 more Smart Citation

Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications

Uno-Eder

2023

JAT

View full text Add to dashboard Cite

Section: See Article Vol 30: 000-000mentioning

confidence: 99%

Section: See Article Vol 30: 000-000mentioning

confidence: 99%

Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications

Uno-Eder

2023

JAT

View full text Add to dashboard Cite

Asia–Pacific Real-World Evolocumab Use, LDL-C Reduction, Physician Goals, and Patient Perceptions: HALES Observational Study

Tse,

Chang,

Colquhoun

et al. 2024

Cardiol Ther

View full text Add to dashboard Cite

Introduction Real-world data are needed to understand the effectiveness of new therapeutic options for low-density lipoprotein cholesterol (LDL-C) reduction in Asia–Pacific clinical practice. Description of evolocumab use among adults with establis H ed A therosclerotic cardiovascu L ar diseas E or hypercholesterolemia in A S ia–Pacific region (HALES) was performed to better understand characteristics of and clinical decision-making for adults with established atherosclerotic cardiovascular disease/hypercholesterolemia after local evolocumab approval. Methods The HALES observational study, conducted at 33 sites (Hong Kong, Thailand, South Korea, Singapore, Taiwan, and Australia) comprised (1) chart review of patients who received evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i), and (2) physician/patient survey and one-time data collection of patients with high cardiovascular risk initiating evolocumab or initiating/continuing non-PCSK9i lipid-lowering therapy. Patients could only enroll in (1) or (2). Results Chart review included 724 very high-risk patients initiating evolocumab from regulatory approval to 2021. From median baseline LDL-C of 3.2 mmol/L (123.7 mg/dL), patients had a median percent change in LDL-C of − 60.8% at 1–6 months. Goal achievement increased from 7.9% to 69.8% for < 1.8 mmol/L (< 70 mg/dL) and 4.4% to 57.8% for < 1.4 mmol/L (< 55 mg/dL) from baseline to 12 months. In the one-time data collection, more patients had ≥ 1.8 mmol/L (≥ 70 mg/dL) baseline LDL-C in the evolocumab vs non-PCSK9i group (95.2% and 48.5%, respectively). Surveys found that physicians applied guideline-recommended treatment targets, and patients demonstrated gaps in understanding cardiovascular risk. Conclusion Real-world, Asia–Pacific data showed that LDL-C reduction after initiating evolocumab was consistent with that observed in other clinical trials and patient populations. Graphical abstract available for this article.· Supplementary Information The online version contains supplementary material available at 10.1007/s40119-024-00384-3.

show abstract